Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapy

We report four dinuclear silver(I) and gold(I) complexes containing two different bidentate N-heterocyclic carbene ligands (bisNHC). One of these complexes 4, shows strong and selective anticancer activity against the human ovarian cancer cell line A2780. Mechanistically, 4 enhances the oxidative st...

Descripción completa

Detalles Bibliográficos
Autores: Quintana, Mireia, Rodriguez-Rius, Alba, Vellé, Alba, Vives, Sonia, Sanz Miguel, Pablo J., Triola Guillem, Gemma
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/271149
Acceso en línea:http://hdl.handle.net/10261/271149
https://api.elsevier.com/content/abstract/scopus_id/85130351392
Access Level:acceso abierto
Palabra clave:Silver
Gold
N-heterocyclic carbene
Ovarian cancer
Oxidative stress
id ES_f42e8d461b0780e0877891ca7d6411ee
oai_identifier_str oai:digital.csic.es:10261/271149
network_acronym_str ES
network_name_str España
repository_id_str
spelling Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapyQuintana, MireiaRodriguez-Rius, AlbaVellé, AlbaVives, SoniaSanz Miguel, Pablo J.Triola Guillem, GemmaSilverGoldN-heterocyclic carbeneOvarian cancerOxidative stressWe report four dinuclear silver(I) and gold(I) complexes containing two different bidentate N-heterocyclic carbene ligands (bisNHC). One of these complexes 4, shows strong and selective anticancer activity against the human ovarian cancer cell line A2780. Mechanistically, 4 enhances the oxidative stress by stimulating reactive oxygen species production and inhibiting the scavenging activity of thioredoxin reductase. Our findings provide evidence that tuning ligand and electronic properties of metal-NHC complexes can modulate their reactivity and selectivity and it may result in potential novel anticancer drugs.We acknowledge financial support from Ministerio de Ciencia e Innovación, Spain (RTI2018-096323-B-I00), the Marie Curie Career Integration Grants (PCIG12-GA-2012-33835), the Max Planck Society (MPG Partner Group), the Aragon Government (E42_20R) and the University of Zaragoza.Peer reviewedElsevierMinisterio de Ciencia, Innovación y Universidades (España)Agencia Estatal de Investigación (España)European CommissionGobierno de AragónEuropean CommissionUniversidad de ZaragozaMax Planck SocietyConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202220222022info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/271149https://api.elsevier.com/content/abstract/scopus_id/85130351392reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-096323-B-I00Bioorganic & medicinal chemistryThe underlying dataset has been published as supplementary material of the article in the publisher platform at DOI 10.1016/j.bmc.2022.116814https://doi.org/10.1016/j.bmc.2022.116814Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2711492026-05-22T06:33:51Z
dc.title.none.fl_str_mv Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapy
title Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapy
spellingShingle Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapy
Quintana, Mireia
Silver
Gold
N-heterocyclic carbene
Ovarian cancer
Oxidative stress
title_short Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapy
title_full Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapy
title_fullStr Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapy
title_full_unstemmed Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapy
title_sort Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapy
dc.creator.none.fl_str_mv Quintana, Mireia
Rodriguez-Rius, Alba
Vellé, Alba
Vives, Sonia
Sanz Miguel, Pablo J.
Triola Guillem, Gemma
author Quintana, Mireia
author_facet Quintana, Mireia
Rodriguez-Rius, Alba
Vellé, Alba
Vives, Sonia
Sanz Miguel, Pablo J.
Triola Guillem, Gemma
author_role author
author2 Rodriguez-Rius, Alba
Vellé, Alba
Vives, Sonia
Sanz Miguel, Pablo J.
Triola Guillem, Gemma
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Ciencia, Innovación y Universidades (España)
Agencia Estatal de Investigación (España)
European Commission
Gobierno de Aragón
European Commission
Universidad de Zaragoza
Max Planck Society
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Silver
Gold
N-heterocyclic carbene
Ovarian cancer
Oxidative stress
topic Silver
Gold
N-heterocyclic carbene
Ovarian cancer
Oxidative stress
description We report four dinuclear silver(I) and gold(I) complexes containing two different bidentate N-heterocyclic carbene ligands (bisNHC). One of these complexes 4, shows strong and selective anticancer activity against the human ovarian cancer cell line A2780. Mechanistically, 4 enhances the oxidative stress by stimulating reactive oxygen species production and inhibiting the scavenging activity of thioredoxin reductase. Our findings provide evidence that tuning ligand and electronic properties of metal-NHC complexes can modulate their reactivity and selectivity and it may result in potential novel anticancer drugs.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/271149
https://api.elsevier.com/content/abstract/scopus_id/85130351392
url http://hdl.handle.net/10261/271149
https://api.elsevier.com/content/abstract/scopus_id/85130351392
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-096323-B-I00
Bioorganic & medicinal chemistry
The underlying dataset has been published as supplementary material of the article in the publisher platform at DOI 10.1016/j.bmc.2022.116814
https://doi.org/10.1016/j.bmc.2022.116814
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424447723667456
score 15.812429

Similares en LA Referencia